Valerie Hox1, Michael P O'Connell1, Jonathan J Lyons1, Paul Sackstein1, Thomas Dimaggio1, Nina Jones2, Celeste Nelson1, Manfred Boehm3, Steven M Holland4, Alexandra F Freeman4, David J Tweardy5, Ana Olivera1, Dean D Metcalfe1, Joshua D Milner6. 1. Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 2. Clinical Research Directorate/CMRP, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Md. 3. Center for Molecular Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md. 4. Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 5. Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, Md. 6. Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address: jdmilner@niaid.nih.gov.
Abstract
BACKGROUND: During IgE-mediated immediate hypersensitivity reactions, vascular endothelial cells permeabilize in response to mast cell mediators. We have demonstrated previously that patients and mice with signal transducer and activator of transcription 3 (STAT3) mutations (autosomal dominant hyper-IgE syndrome [AD-HIES]) are partially protected from anaphylaxis. OBJECTIVES: We sought to study the mechanism by which STAT3 contributes to anaphylaxis and determine whether small-molecule inhibition of STAT3 can prevent anaphylaxis. METHODS: Using unaffected and STAT3-inhibited or genetic loss-of-function samples, we performed histamine skin prick tests, investigated the contribution of STAT3 to animal models of anaphylaxis, and measured endothelial cell permeability, gene and protein expression, and histamine receptor-mediated signaling. RESULTS: Although mouse mast cell degranulation was minimally affected by STAT3 blockade, mast cell mediator-induced anaphylaxis was blunted in Stat3 mutant mice with AD-HIES and in wild-type mice subjected to small-molecule STAT3 inhibition. Histamine skin prick test responses were diminished in patients with AD-HIES. Human umbilical vein endothelial cells derived from patients with AD-HIES or treated with a STAT3 inhibitor did not signal properly through Src or cause appropriate dissolution of the adherens junctions made up of the proteins vascular endothelial-cadherin and β-catenin. Furthermore, we found that diminished STAT3 target microRNA17-92 expression in human umbilical vein endothelial cells from patients with AD-HIES is associated with increased phosphatase and tensin homolog (PTEN) expression, which inhibits Src, and increased E2F transcription factor 1 expression, which regulates β-catenin cellular dynamics. CONCLUSIONS: These data demonstrate that STAT3-dependent transcriptional activity regulates critical components for the architecture and functional dynamics of endothelial junctions, thus permitting vascular permeability. Published by Elsevier Inc.
BACKGROUND: During IgE-mediated immediate hypersensitivity reactions, vascular endothelial cells permeabilize in response to mast cell mediators. We have demonstrated previously that patients and mice with signal transducer and activator of transcription 3 (STAT3) mutations (autosomal dominant hyper-IgE syndrome [AD-HIES]) are partially protected from anaphylaxis. OBJECTIVES: We sought to study the mechanism by which STAT3 contributes to anaphylaxis and determine whether small-molecule inhibition of STAT3 can prevent anaphylaxis. METHODS: Using unaffected and STAT3-inhibited or genetic loss-of-function samples, we performed histamine skin prick tests, investigated the contribution of STAT3 to animal models of anaphylaxis, and measured endothelial cell permeability, gene and protein expression, and histamine receptor-mediated signaling. RESULTS: Although mouse mast cell degranulation was minimally affected by STAT3 blockade, mast cell mediator-induced anaphylaxis was blunted in Stat3 mutant mice with AD-HIES and in wild-type mice subjected to small-molecule STAT3 inhibition. Histamine skin prick test responses were diminished in patients with AD-HIES. Human umbilical vein endothelial cells derived from patients with AD-HIES or treated with a STAT3 inhibitor did not signal properly through Src or cause appropriate dissolution of the adherens junctions made up of the proteins vascular endothelial-cadherin and β-catenin. Furthermore, we found that diminished STAT3 target microRNA17-92 expression in human umbilical vein endothelial cells from patients with AD-HIES is associated with increased phosphatase and tensin homolog (PTEN) expression, which inhibits Src, and increased E2F transcription factor 1 expression, which regulates β-catenin cellular dynamics. CONCLUSIONS: These data demonstrate that STAT3-dependent transcriptional activity regulates critical components for the architecture and functional dynamics of endothelial junctions, thus permitting vascular permeability. Published by Elsevier Inc.
Entities:
Keywords:
Allergy; autosomal dominant hyper-IgE syndrome; immunology; innate immunity; signal transducer and activator of transcription 3
Authors: Michael J Nemeth; Lilia Topol; Stacie M Anderson; Yingzi Yang; David M Bodine Journal: Proc Natl Acad Sci U S A Date: 2007-09-19 Impact factor: 11.205
Authors: Bingbing Dai; Jieru Meng; Michael Peyton; Luc Girard; William G Bornmann; Lin Ji; John D Minna; Bingliang Fang; Jack A Roth Journal: Cancer Res Date: 2011-03-28 Impact factor: 12.701
Authors: Kyung Sun Lee; So Ri Kim; Seoung Ju Park; Ho Kyung Lee; Hee Sun Park; Kyung Hoon Min; Sun Mi Jin; Yong Chul Lee Journal: Mol Pharmacol Date: 2006-03-09 Impact factor: 4.436
Authors: Andrea M Siegel; Kelly D Stone; Glenn Cruse; Monica G Lawrence; Ana Olivera; Mi-yeon Jung; John S Barber; Alexandra F Freeman; Steven M Holland; Michelle O'Brien; Nina Jones; Celeste G Nelson; Laura B Wisch; Heidi H Kong; Avanti Desai; Orly Farber; Alasdair M Gilfillan; Juan Rivera; Joshua D Milner Journal: J Allergy Clin Immunol Date: 2013-11-01 Impact factor: 10.793
Authors: Sarah E Flanagan; Emma Haapaniemi; Mark A Russell; Richard Caswell; Hana Lango Allen; Elisa De Franco; Timothy J McDonald; Hanna Rajala; Anita Ramelius; John Barton; Kaarina Heiskanen; Tarja Heiskanen-Kosma; Merja Kajosaari; Nuala P Murphy; Tatjana Milenkovic; Mikko Seppänen; Åke Lernmark; Satu Mustjoki; Timo Otonkoski; Juha Kere; Noel G Morgan; Sian Ellard; Andrew T Hattersley Journal: Nat Genet Date: 2014-07-20 Impact factor: 38.330
Authors: Zeinab A El-Sayed; Dalia H El-Ghoneimy; José A Ortega-Martell; Nesrine Radwan; Juan C Aldave; Waleed Al-Herz; Maryam A Al-Nesf; Antonio Condino-Neto; Theresa Cole; Brian Eley; Nahla H H Erwa; Sara Espinosa-Padilla; Emilia Faria; Nelson A Rosario Filho; Ramsay Fuleihan; Nermeen Galal; Elizabeth Garabedian; Mary Hintermeyer; Kohsuke Imai; Carla Irani; Ebtihal Kamal; Nadia Kechout; Adam Klocperk; Michael Levin; Tomas Milota; Monia Ouederni; Roberto Paganelli; Claudio Pignata; Farah N Qamar; Isabella Quinti; Sonia Qureshi; Nita Radhakrishnan; Nima Rezaei; John Routes; Surjit Singh; Sangeetha Siniah; Intisar Abdel-Hakam Taha; Luciana K Tanno; Ben Van Dort; Alla Volokha; Kathleen Sullivan Journal: World Allergy Organ J Date: 2022-06-17 Impact factor: 5.516
Authors: Stephanie C Harrison; Christo Tsilifis; Mary A Slatter; Zohreh Nademi; Austen Worth; Paul Veys; Mark J Ponsford; Stephen Jolles; Waleed Al-Herz; Terence Flood; Andrew J Cant; Rainer Doffinger; Gabriela Barcenas-Morales; Ben Carpenter; Rachael Hough; Ásgeir Haraldsson; Jennifer Heimall; Bodo Grimbacher; Mario Abinun; Andrew R Gennery Journal: J Clin Immunol Date: 2021-02-01 Impact factor: 8.317
Authors: Alma Yuste-Montalvo; Sergio Fernandez-Bravo; Tamara Oliva; Carlos Pastor-Vargas; Diana Betancor; María José Goikoetxea; José Julio Laguna; Juan Antonio López; Gloria Alvarez-Llamas; Javier Cuesta-Herranz; Marta Martin-Lorenzo; Vanesa Esteban Journal: Front Immunol Date: 2021-06-25 Impact factor: 7.561